通过一种新型LncRNA A930015D03Rik的KLF12转录激活可以增强黑色素瘤转移
Meng Xiang1, Ziyi Li2, Jie Su2
1Chongqing Key Laboratory of Human Embryo Engineering and Precision Medicine, Center for Reproductive Medicine, Women and Children's Hospital of Chongqing Medical University, Chongqing, China; Chongqing Clinical Research Center for Reproductive Medicine, Chongqing Health Center for Women and Children, Chongqing, China; State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China.
International journal of biological macromolecules
|April 4, 2025
概括
黑色素瘤细胞使用外体转移 lncRNA A930015D03Rik,从而增加KLF12表达. 这通过激活炎症和NF-κB通路来促进癌症的扩散,阻碍瘤的抑制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症转移研究 癌症转移研究
背景情况:
- 黑色素瘤转移是癌症进展的致命方面,治疗选择有限.
- 转录因子KLF12在黑色素瘤中的作用及其与细胞外囊泡 (EV) 介导的通信的相互作用尚未得到充分理解.
研究的目的:
- 研究转移性黑色素瘤细胞如何通过EV货物转移利用KLF12介导的途径来促进侵略性的表型.
- 为了阐明KLF12,细胞外囊泡和黑色素瘤转移之间的调节相互作用.
主要方法:
- 对转移性黑色素瘤细胞间通信机制的分析.
- 研究长非编码RNA (lncRNA) 的外体介导转移 A930015D03Rik.
- 涉及lncRNA A930015D03Rik,miR-204-5p和KLF12的监管网络的探索.
主要成果:
- 高度转移的黑色素瘤细胞转移出体的lncRNA A930015D03Rik,它作为miR-204-5p的竞争性内源RNA (ceRNA) 起作用.
- 这种海绵效应会增加KLF12的表达,从而激活促癌途径 (炎症,NF-κB) 和抑制瘤抑制剂 (P53,氧化酸化).
- 已识别的外体-lncRNA-KLF12轴增强黑色素瘤细胞迁移和入侵,推动恶性进展.
结论:
- 一个涉及瘤衍生的EVs,IncRNA A930015D03Rik和KLF12的新机制调节了黑色素瘤转移的可塑性.
- 这种外基因组前回路解释了KLF12的上下文依赖的转移性功能.
- 这些发现为抑制黑色素瘤转移提供了潜在的治疗点.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
01:07MAPK Signaling Cascades
5.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
03:18Non-LTR Retrotransposons
11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:06Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K